Zacks Research Upgrades Harvard Bioscience (NASDAQ:HBIO) to “Hold”

Harvard Bioscience (NASDAQ:HBIO) was upgraded by analysts at Zacks Research to a “hold” rating in a research note issued on Thursday,Zacks.com reports.

Several other research analysts also recently issued reports on HBIO. Benchmark dropped their price objective on shares of Harvard Bioscience from $3.00 to $2.00 and set a “speculative buy” rating on the stock in a report on Wednesday, September 10th. Wall Street Zen raised Harvard Bioscience from a “hold” rating to a “buy” rating in a report on Monday, November 17th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Harvard Bioscience in a report on Monday. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $2.00.

Harvard Bioscience Stock Performance

Shares of HBIO traded down $0.00 during mid-day trading on Thursday, hitting $0.74. The company’s stock had a trading volume of 550,926 shares, compared to its average volume of 1,019,486. The stock’s 50-day moving average is $0.58 and its two-hundred day moving average is $0.51. The firm has a market capitalization of $33.03 million, a PE ratio of -0.61 and a beta of 1.53. Harvard Bioscience has a one year low of $0.28 and a one year high of $2.30.

Institutional Trading of Harvard Bioscience

A number of large investors have recently bought and sold shares of HBIO. AMH Equity Ltd grew its holdings in shares of Harvard Bioscience by 15.4% during the third quarter. AMH Equity Ltd now owns 4,047,535 shares of the medical instruments supplier’s stock worth $1,775,000 after purchasing an additional 538,832 shares during the last quarter. Acadian Asset Management LLC lifted its position in Harvard Bioscience by 7.8% during the 1st quarter. Acadian Asset Management LLC now owns 1,077,069 shares of the medical instruments supplier’s stock worth $606,000 after buying an additional 78,276 shares in the last quarter. Two Sigma Investments LP grew its holdings in Harvard Bioscience by 139.7% during the 3rd quarter. Two Sigma Investments LP now owns 474,157 shares of the medical instruments supplier’s stock worth $208,000 after acquiring an additional 276,372 shares during the last quarter. Williams & Novak LLC increased its position in Harvard Bioscience by 158.5% in the 3rd quarter. Williams & Novak LLC now owns 275,500 shares of the medical instruments supplier’s stock valued at $121,000 after acquiring an additional 168,930 shares in the last quarter. Finally, Pasadena Private Wealth LLC increased its position in Harvard Bioscience by 23.2% in the 2nd quarter. Pasadena Private Wealth LLC now owns 243,911 shares of the medical instruments supplier’s stock valued at $108,000 after acquiring an additional 45,872 shares in the last quarter. 80.87% of the stock is currently owned by institutional investors.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.